NCT03226626View on ClinicalTrials.gov

Tumescent Anesthesia Antibiotic Delivery (TAAD)

PHASE2/PHASE3UnknownINTERVENTIONAL
Enrollment

330

Participants

Timeline

Start Date

December 1, 2021

Primary Completion Date

January 1, 2022

Study Completion Date

July 31, 2022

Conditions
Surgical Site InfectionThrombosisSepsis
Interventions
DRUG

Tumescent Anesthesia and antibiotic delivery (TAAD) plus IVAD

Concomitant tumescent anesthesia antibiotic delivery (TAAD) \& Intravenous antibiotic delivery (IVAD).

DEVICE

SubQKath

The device intervention consists of using the SubQKath device to provide subcutaneous delivery of antibiotics.

Sponsors

Lead Sponsor

HK Surgical, Inc.
All Listed Sponsors
collaborator

University of California, Riverside

OTHER

lead

HK Surgical, Inc.

INDUSTRY